18β-Glycyrrhetinic acid: its core biological properties and dermatological applications.
A Kowalska, U Kalinowska-Lis
https://pubmed.ncbi.nlm.nih.gov/31166601/Actively Recruiting
Led by ISISPHARMA · Updated on 2026-09-08
50
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are evaluating a dermocosmetic product designed to reduce facial redness and visible blood vessels linked to erythematotelangiectatic rosacea. This study compares the dermocosmetic product to a placebo, applied to opposite sides of the face, both alone and alongside vascular laser treatment. The trial is randomized, double-blind, placebo-controlled, and involves about 50 adult participants with mild to severe rosacea. Participants will apply the dermocosmetic product on one side of the face and the placebo on the other side twice daily for two months. After this period, both products continue to be used in combination with three sessions of vascular laser treatment performed at set intervals. This split-face design allows direct comparison of the treatments effects over an eight-month period. During the study, participants will attend regular clinical visits for assessments, including clinical evaluations of redness and blood vessels, standardized scoring, and patient questionnaires. Safety will be closely monitored by tracking local tolerability and any adverse events. The main outcome measured is the change in Investigator Global Assessment IGA scores on each side of the face after eight months of treatment.
CONDITIONS
Dermocosmetic Treatment for Facial Redness in Rosacea With or Without Laser Therapy
C
Chloe GOYET, Master degree
A
Amelie CLEMENT, Engineering degree
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
ISISPHARMA
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 8 months
Participants apply the dermocosmetic product to one side of the face and placebo to the other side twice daily for 2 months. Following this, they continue these applications while receiving three vascular laser treatment sessions at regular intervals.
Regular clinical visits for assessments and questionnaires
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
A Kowalska, U Kalinowska-Lis
https://pubmed.ncbi.nlm.nih.gov/31166601/M Schaller, L M C Almeida, A Bewley...
https://pubmed.ncbi.nlm.nih.gov/31392722/Hanane Chajra, Mahdi Nadim, Daniel Auriol...
https://pubmed.ncbi.nlm.nih.gov/26491365/M Schaller, L M C Almeida, A Bewley...
https://pubmed.ncbi.nlm.nih.gov/27861741/J Tan, L M C Almeida, A Bewley...
https://pubmed.ncbi.nlm.nih.gov/27718519/B Cribier
https://pubmed.ncbi.nlm.nih.gov/34893359/ISISPHARMA
Lead Sponsor